DK3529262T3 - Fremgangsmåder til fremme af t-cellerespons - Google Patents

Fremgangsmåder til fremme af t-cellerespons Download PDF

Info

Publication number
DK3529262T3
DK3529262T3 DK17797066.2T DK17797066T DK3529262T3 DK 3529262 T3 DK3529262 T3 DK 3529262T3 DK 17797066 T DK17797066 T DK 17797066T DK 3529262 T3 DK3529262 T3 DK 3529262T3
Authority
DK
Denmark
Prior art keywords
promoting
procedures
cell response
cell
response
Prior art date
Application number
DK17797066.2T
Other languages
Danish (da)
English (en)
Inventor
Elise Chiffoleau
Géraldine TEPPAZ
Nicolas Poirier
Bernard Vanhove
Vanessa Gauttier
Original Assignee
Inst Nat Sante Rech Med
Univ Nantes
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Nantes, Ose Immunotherapeutics filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3529262T3 publication Critical patent/DK3529262T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17797066.2T 2016-10-21 2017-10-20 Fremgangsmåder til fremme af t-cellerespons DK3529262T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16306381 2016-10-21
EP17305988 2017-07-24
PCT/EP2017/076911 WO2018073440A1 (fr) 2016-10-21 2017-10-20 Procédés pour favoriser la réponse des lymphocytes t

Publications (1)

Publication Number Publication Date
DK3529262T3 true DK3529262T3 (da) 2021-09-20

Family

ID=60293924

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17797066.2T DK3529262T3 (da) 2016-10-21 2017-10-20 Fremgangsmåder til fremme af t-cellerespons

Country Status (20)

Country Link
US (2) US11365257B2 (fr)
EP (2) EP3529262B1 (fr)
JP (2) JP7032396B6 (fr)
KR (1) KR102646708B1 (fr)
CN (1) CN110291102A (fr)
AU (1) AU2017345286B2 (fr)
CA (1) CA3039348C (fr)
CY (1) CY1124584T1 (fr)
DK (1) DK3529262T3 (fr)
ES (1) ES2883678T3 (fr)
HR (1) HRP20211544T1 (fr)
HU (1) HUE056016T2 (fr)
IL (1) IL266111B (fr)
LT (1) LT3529262T (fr)
MA (1) MA46570B1 (fr)
MD (1) MD3529262T2 (fr)
PL (1) PL3529262T3 (fr)
RS (1) RS62463B1 (fr)
SI (1) SI3529262T1 (fr)
WO (1) WO2018073440A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3529262T1 (sl) * 2016-10-21 2021-12-31 Inserm - Institut National De La Sante Et De La Recherche Medicale Postopki za spodbujanje odgovora T-celic
EP3589291A4 (fr) 2017-02-28 2020-11-25 Vor Biopharma, Inc. Compositions et méthodes d'inhibition de protéines spécifiques d'une lignée
CN113423725A (zh) 2018-08-28 2021-09-21 Vor生物制药股份有限公司 遗传工程化造血干细胞及其用途
CN115151309A (zh) 2019-12-05 2022-10-04 Ose免疫疗法 抗clec-1a抗体及其抗原结合片段
WO2022258714A1 (fr) 2021-06-08 2022-12-15 Ose Immunotherapeutics Anticorps humanisés anti-clec-1a et fragments de liaison à l'antigène de ceux-ci et mimétiques de ceux-ci
CN118510534A (zh) * 2021-11-09 2024-08-16 Ose免疫疗法 Clec-1配体的识别及其用途
WO2024028347A1 (fr) 2022-08-01 2024-02-08 Ose Immunotherapeutics Molécule hybride fc-clec-1 hétérodimère et ses utilisations

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ES2338791T3 (es) 1992-08-21 2010-05-12 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
WO1995002420A2 (fr) 1993-07-15 1995-01-26 Cancer Research Campaign Technology Ltd. Bioprecurseurs d'inhibiteurs de la tyrosine-kinase de proteines
EP0690452A3 (fr) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Mémoire électriquement effaçable et procédé d'effacement
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
DK0892789T4 (da) 1996-04-12 2010-04-06 Warner Lambert Co Irreversible inhibitorer af tyrosin kinaser
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2376957A1 (fr) 1999-06-30 2001-01-04 Merck & Co., Inc. Composes inhibiteurs de la src kinase
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
CA2376951A1 (fr) 1999-06-30 2001-01-04 Peter J. Sinclair Composes inhibiteurs de la kinase src
EE200200123A (et) 1999-09-10 2003-08-15 Merck & Co., Inc. Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine
WO2001028993A2 (fr) 1999-10-19 2001-04-26 Merck & Co. Inc. Inhibiteurs tyrosine kinase
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
SK286628B6 (sk) 1999-10-19 2009-02-05 Merck & Co., Inc. Inhibítory tyrozín-kinázy, farmaceutický prostriedok s ich obsahom a ich použitie
EP1783141A1 (fr) * 1999-11-15 2007-05-09 Miltenyi Biotec GmbH Fragments anticorps spécifiques aux cellules dendritiques, compositions et procédés d'utilisation de ceux-ci, antigènes ainsi reconnus et cellules ainsi obtenues
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60208792T2 (de) 2001-06-22 2006-08-31 Merck & Co., Inc. Tyrosin-kinase inhibitoren
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (fr) 2001-08-30 2003-03-13 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
US8246959B1 (en) 2003-08-01 2012-08-21 University Of Washington Dendritic cell-associated lectin-like molecules, compositions and methods of use
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
EP2129692A4 (fr) * 2007-02-23 2010-12-15 Baylor Res Inst Activation de cellules humaines presentant un antigene par l'intermediaire de clec-6
WO2011105424A1 (fr) * 2010-02-23 2011-09-01 国立大学法人東京大学 Stimulant d'immunorécepteur de cellules dendritiques
AR101829A1 (es) * 2014-07-21 2017-01-18 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
SI3529262T1 (sl) 2016-10-21 2021-12-31 Inserm - Institut National De La Sante Et De La Recherche Medicale Postopki za spodbujanje odgovora T-celic

Also Published As

Publication number Publication date
US20190309075A1 (en) 2019-10-10
EP3950709A1 (fr) 2022-02-09
MA46570A (fr) 2021-03-31
AU2017345286B2 (en) 2023-08-03
WO2018073440A1 (fr) 2018-04-26
AU2017345286A1 (en) 2019-04-18
JP2020503252A (ja) 2020-01-30
EP3529262B1 (fr) 2021-07-21
EP3950709B1 (fr) 2024-02-14
LT3529262T (lt) 2021-11-10
JP7404418B2 (ja) 2023-12-25
JP2022065159A (ja) 2022-04-26
ES2883678T3 (es) 2021-12-09
MA46570B1 (fr) 2021-10-29
MD3529262T2 (ro) 2022-01-31
CA3039348C (fr) 2023-09-05
JP7032396B2 (ja) 2022-03-08
CA3039348A1 (fr) 2018-04-26
US20220281983A1 (en) 2022-09-08
KR102646708B1 (ko) 2024-03-12
JP7032396B6 (ja) 2022-03-22
IL266111A (en) 2019-06-30
IL266111B (en) 2022-09-01
HUE056016T2 (hu) 2022-01-28
HRP20211544T1 (hr) 2022-01-07
US11365257B2 (en) 2022-06-21
EP3529262A1 (fr) 2019-08-28
KR20190068605A (ko) 2019-06-18
PL3529262T3 (pl) 2021-12-27
SI3529262T1 (sl) 2021-12-31
JP7404418B6 (ja) 2024-01-26
CN110291102A (zh) 2019-09-27
RS62463B1 (sr) 2021-11-30
CY1124584T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
DK3463248T3 (da) Anordnnger til anvendelse af lægemiddelanordninger
DK3346961T3 (da) Anordning til stomi
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3300500T3 (da) Triazolagonister af apj-receptoren
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3126373T3 (da) Fremgangsmåde til fremstilling af amg 416
DK3303618T3 (da) Fremgangsmåder til prognose af prostatacancer
DK3507408T3 (da) Fremgangsmåde til fremstilling af nonwoven
DK3529262T3 (da) Fremgangsmåder til fremme af t-cellerespons
DK3529233T3 (da) Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider
DK3519094T3 (da) System til forberedelse af en prøve
DK3222717T3 (da) Fremgangsmåde til at amplificere cirkulært dna
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3164716T3 (da) Fremgangsmåde til diagnosticering af neurodegenerative sygdomme
DK3274143T3 (da) Fremgangsmåde til fremstilling af lignocellulosematerialer
DK3166855T3 (da) Fremgangsmåde for tilvejebringelse af foldelinjer
DE112016005541A5 (de) Arylierungsverfahren
DK3302788T3 (da) Fremgangsmåde til fremstilling af en sorbent
DK3507282T3 (da) Fremgangsmåde til fremstilling af indolcarboxamidforbindelser
DK3467005T3 (da) Fremgangsmåde til opnåelse af bionedbrydeligt polyesteretheramid